Work

659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.918

Authors: S. Chowdhury, A. Patnaik, D. Campbell, J. Shapiro, A.H. Bryce, R. McDermott, B. Sautois, N.J. Vogelzang, R. Bambury, E. Voog, J. Zhang, M. Green, J. Beltman, D. Despain, A.D. Simmons, S.P. Watkins, A. Golsorkhi, J. Xiao, W. Abida

Institutions: Guy's Hospital, Sarah Cannon Research Institute, University of Chicago, Barwon Health, Geelong Hospital, Cabrini Hospital, Mayo Clinic, Mayo Clinic Hospital, Tallaght University Hospital, Centre Hospitalier Universitaire de Liège, Comprehensive Cancer Centers of Nevada, Cork University Hospital, Centre Jean Bernard, Clinique Victor Hugo, Moffitt Cancer Center, Certara (United States), Clovis Oncology (United States), Clovis Oncology (United Kingdom), Memorial Sloan Kettering Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Merck, Sanofi, Clovis Oncology, Eisai, Astellas Pharma, Ipsen, Merck Sharp and Dohme

OpenAlex ID: W3087966061

FWCI: 0.181

Cites:

Cited by: 2

Related to: 10